Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile

STOCKHOLM, Oct. 31, 2024 /PRNewswire/ — BioArctic AB’s (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer’s Disease, CTAD, congress, held in Madrid, Spain, and virtually, October 29 to November 1….